

FEEDBACK-REGULATED AND BIOELECTRONIC DRUG DELIVERY SYSTEMS: TOWARDS CLOSED-LOOP THERAPEUTICS

Munaparathi Pooja^{*1}, Shailaja Pashikanti², Naga Lakshmi Ponnada³

¹Student, A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam.

²Associate Professor, A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam.

³Research Scholar, A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam.

Article Received: 13 August 2026 | Article Revised: 03 September 2026 | Article Accepted: 23 September 2026

***Corresponding Author: Munaparathi Pooja**

Student, A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam.

DOI: <https://doi.org/10.5281/zenodo.23053662>

How to cite this Article: Munaparathi Pooja, Shailaja Pashikanti, Naga Lakshmi Ponnada (2026) FEEDBACK-REGULATED AND BIOELECTRONIC DRUG DELIVERY SYSTEMS: TOWARDS CLOSED-LOOP THERAPEUTICS. World Journal of Pharmaceutical Science and Research, 5(10), 154-174.



Copyright © 2026 Munaparathi Pooja | World Journal of Pharmaceutical Science and Research.

This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

ABSTRACT

Conventional drug delivery systems generally operate as open-loop platforms based on fixed dosing regimens that do not account for dynamic physiological variations during disease progression. This often leads to suboptimal therapeutic outcomes, fluctuations in drug concentration, and increased risk of adverse drug reactions. To overcome these limitations, feedback-regulated and bioelectronic drug delivery systems have emerged as advanced therapeutic strategies capable of responding to real-time physiological signals. Feedback-regulated systems utilize disease-associated biomarkers such as glucose levels, pH variations, enzymatic activity, and inflammatory mediators to autonomously control drug release, thereby mimicking natural biological feedback mechanisms that maintain physiological homeostasis. Bioelectronic drug delivery systems further enhance therapeutic precision by integrating biosensors, microelectronics, control algorithms, and programmable actuators for real-time monitoring and automated drug administration. The integration of these technologies enables closed-loop therapeutic platforms capable of continuous sensing, signal processing, and adaptive drug delivery. These systems have demonstrated promising potential in the management of chronic diseases including diabetes, neurological disorders, cardiovascular diseases, inflammatory conditions, and cancer. Overall, closed-loop bioelectronic drug delivery systems represent a significant advancement toward intelligent, personalized, and precision medicine, although challenges related to sensor stability, device biocompatibility, and regulatory approval remain to be addressed.

KEYWORDS: Closed-loops drug delivery; Feedback-regulated systems; Bioelectronic medicine; Smart drug delivery; Precision therapeutics.

1. INTRODUCTION

Drug delivery systems (DDS) have undergone remarkable evolution over the past several decades, progressing from conventional dosage forms to controlled, targeted, and stimuli-responsive platforms aimed at improving therapeutic efficacy and patient compliance.^[27,45,48,49] Despite these advances, the majority of currently available drug delivery systems still rely on fixed dosing regimens that are predetermined during formulation development or clinical prescription.^[1,2,50] Such approaches do not adequately account for the dynamic and heterogeneous nature of human physiology, disease progression, and patient-specific variability.^[1,2,27] Most conventional and controlled drug delivery systems function as **open-loop systems**, in which drug release occurs independently of real-time physiological feedback.^[1,13,14] In open-loop therapy, dose adjustments are typically based on intermittent clinical measurements, population-based dosing guidelines, or patient-reported outcomes.^[1,2,51] This approach often leads to fluctuations in drug concentration, resulting in periods of subtherapeutic exposure or excessive dosing.^[1,2,13] Consequently, open-loop systems are frequently associated with reduced therapeutic efficacy, increased adverse drug reactions, and poor long-term disease control.^[1,2,27] Chronic and complex diseases such as diabetes mellitus, neurological disorders, cardiovascular diseases, inflammatory conditions, and hormonal imbalances require continuous monitoring and precise regulation of therapeutic agents.^[3,7,20,23,51,52,53] These conditions are characterized by rapidly changing physiological parameters, circadian variations, and inter- and intra-patient variability in pharmacokinetics and pharmacodynamics.^[1,2,20,51,52,53] Fixed dosing strategies are inherently inadequate for managing such dynamic disease states, highlighting the need for more intelligent and adaptive therapeutic approaches.^[1,13,14] To address these limitations, **smart drug delivery systems** have emerged, incorporating materials and mechanisms capable of responding to internal or external stimuli such as pH, temperature, enzymes, glucose, or inflammatory markers.^[13,38-49] While stimuli-responsive systems represent a significant improvement over traditional DDS, many of these platforms still operate without real-time feedback control and lack the ability to continuously fine-tune drug release based on the therapeutic outcome.^[13,38,39,40,48,49]

In this context, **feedback-regulated drug delivery systems** have gained considerable attention as advanced therapeutic platforms that autonomously adjust drug release in response to physiological signals.^[1,13,38,39,40] These systems are inspired by natural biological feedback mechanisms that maintain homeostasis in the human body.^[38,40,42] By sensing disease-related biomarkers and modulating drug release accordingly, feedback-regulated systems minimize drug overexposure, reduce adverse effects, and improve therapeutic precision.^[1,13,39-43] Parallel to these developments, rapid progress in microelectronics, biosensors, and digital technologies has given rise to **bioelectronic drug delivery systems**.^[3-6,10-12] Bioelectronics enable direct interfacing between electronic devices and biological systems, allowing real-time sensing of physiological signals, data processing, and programmable therapeutic intervention.^[3,7,10,23,25] When integrated with drug delivery platforms, bioelectronics provide unprecedented control over dose, timing, and duration of drug administration.^[9-14,18] The convergence of feedback-regulated drug delivery with bioelectronic technologies has led to the emergence of **closed-loop therapeutic systems**.^[1,3,10,13,14] In closed-loop systems, continuous sensing, decision-making, and drug delivery occur in an automated cycle, with minimal external intervention.^[1,10,13,14] These systems dynamically maintain therapeutic parameters within a desired range, closely mimicking physiological regulation and enabling personalized, adaptive therapy.^[1,13,20,27,51-53] Closed-loop bioelectronic drug delivery systems represent a paradigm shift in pharmacotherapy, moving beyond conventional “one-dose-fits-all” approaches toward precision medicine.^[1,3,7,27,51-53] By integrating pharmaceutical sciences with bioelectronics, control engineering, and digital health, these systems offer the potential for improved disease control, enhanced patient safety, and reduced

healthcare burden.^[1,3-5,9,14] The present review aims to provide a comprehensive overview of feedback-regulated and bioelectronic drug delivery systems as enabling technologies for closed-loop therapeutics. The review discusses fundamental concepts, system components, integration strategies, clinical applications, advantages, challenges, regulatory and ethical considerations, and future perspectives, highlighting the potential of closed-loop systems to redefine the future of drug delivery and therapeutic management.

2. Concept of Closed-Loop Therapeutics

Closed-loop therapeutics represent an advanced paradigm in drug delivery and disease management; wherein therapeutic intervention is continuously adjusted based on real-time physiological feedback from the patient.^[1,3,10,13] Unlike conventional drug delivery approaches that rely on predefined dosing regimens, closed-loop systems dynamically sense biological signals, process this information, and modulate drug release automatically to maintain the desired therapeutic outcome.^[1,13,14] This approach closely mimics natural physiological homeostasis and is therefore considered a cornerstone of precision and personalized medicine.^[1,27,38,42]

2.1 Definition of Closed-Loop Drug Delivery

Closed-loop drug delivery systems are self-regulating therapeutic platforms that integrate sensing, decision-making, and actuation in a continuous feedback cycle.^[1,10,13,14] In these systems, drug administration is not fixed or manually adjusted but is automatically regulated in response to changes in specific physiological or biochemical parameters such as glucose concentration, pH, enzymatic activity, hormone levels, or neural signals.^[13,38-44] The primary objective of closed-loop drug delivery is to maintain a target therapeutic window by continuously correcting deviations caused by disease progression, environmental factors, or patient-specific variability.^[1,2,13,51-53] This self-adaptive nature distinguishes closed-loop systems from traditional controlled-release formulations and positions them as next-generation therapeutic tools.

2.2 Open-Loop versus Closed-Loop Drug Delivery Systems

Traditional drug delivery systems operate predominantly as **open-loop systems**, where drug dosing is predetermined and independent of real-time physiological feedback.^[1,2,13] In open-loop systems, clinicians rely on population-based dosing guidelines, periodic monitoring, and patient-reported outcomes to adjust therapy. Such approaches often fail to account for intra- and inter-patient variability, leading to suboptimal therapeutic control, adverse drug reactions, or therapeutic failure.^[1,2,20,27] In contrast, **closed-loop systems** continuously monitor relevant biomarkers and adjust drug delivery in real time.^[1,10,13,14] These systems form a feedback cycle in which the output (drug effect) is measured and compared with a desired target, and corrective action is taken automatically. As a result, closed-loop systems offer superior control over drug exposure, improved safety profiles, and enhanced therapeutic efficacy, particularly in chronic and fluctuating disease conditions.^[13,38-40]

2.3 Basic Components of a Closed-Loop Therapeutic System

A closed-loop therapeutic system typically consists of four interdependent components that function synergistically:

2.3.1 Sensors

Sensors are responsible for detecting physiological or biochemical signals relevant to disease management. These may include biosensors for glucose, lactate, pH, enzymes, inflammatory mediators, neurotransmitters, or

electrophysiological signals.^[10-15,35,39] High sensitivity, specificity, stability, and biocompatibility are critical requirements for sensors used in closed-loop systems.^[11,15,16]

2.3.2 Signal Processing Unit

The signal processing unit converts raw sensor data into meaningful information. This step often involves signal amplification, filtering, and digitization to remove noise and ensure accurate interpretation of physiological changes.^[10,14,18,25]

2.3.3 Control Algorithms

Control algorithms act as the decision-making core of closed-loop systems. These algorithms compare the sensed physiological parameter with a predefined target value and calculate the appropriate drug dose or release rate required to restore homeostasis.^[1,13,14,25] Common control strategies include threshold-based control, proportional control, and advanced adaptive algorithms.^[1,14,25,51-53]

2.3.4 Actuator or Drug Release Unit

The actuator executes the therapeutic response by delivering the calculated drug dose. This may involve micro-pumps, electrochemical release mechanisms, stimuli-responsive polymers, or membrane-based delivery systems. The actuator ensures precise, timely, and reproducible drug administration.^[10,12,14,18,25]

2.4 Principles of Feedback Control in Closed-Loop Therapeutics

Feedback control is the fundamental principle underlying closed-loop therapeutics. In a feedback-controlled system, the therapeutic outcome is continuously monitored, and deviations from the desired state trigger corrective actions.^[1,13,38-40]

Negative feedback is most commonly employed, where drug delivery is reduced once the target therapeutic level is achieved, thereby preventing overdose or toxicity.^[38-43,51-55] Feedback control enables closed-loop systems to adapt to dynamic physiological conditions such as circadian rhythms, stress, diet, disease progression, and patient-specific pharmacokinetic variability. By continuously fine-tuning drug delivery, feedback-based systems reduce fluctuations in drug concentration and improve therapeutic stability.^[1,13,20,51-53]

3. Feedback-Regulated Drug Delivery Systems

Feedback-regulated drug delivery systems represent a class of smart therapeutic platforms designed to autonomously adjust drug release in response to real-time physiological or biochemical signals.^[1,13,38-40] These systems are inspired by natural biological feedback mechanisms that maintain homeostasis within the body. By continuously sensing changes in disease-related biomarkers and modulating drug release accordingly, feedback-regulated systems minimize drug overexposure, reduce adverse effects, and enhance therapeutic efficacy.^[38,40,42]

3.1 Overview of Feedback-Regulated Drug Delivery Systems

Conventional controlled drug delivery systems provide sustained or targeted drug release but lack the ability to respond dynamically to changes in the patient's physiological state.^[27,45,48,49] Feedback-regulated drug delivery systems overcome this limitation by incorporating sensing and response mechanisms that allow the system to “decide” when and how much drug to release. In these systems, the therapeutic output is continuously influenced by the biological response to the drug itself. As a result, feedback-regulated systems function as self-correcting platforms that

automatically adjust drug delivery to maintain optimal therapeutic levels. This approach is particularly beneficial for chronic diseases characterized by fluctuating physiological parameters.^[1,13,38-40]

3.2 Mechanism of Feedback Regulation in Drug Delivery

The feedback mechanism in drug delivery operates through a closed cycle involving stimulus detection, signal interpretation, and drug release modulation. When a physiological parameter deviates from its desired range, the system responds by releasing or withholding the drug until equilibrium is restored.^[1,13,38-40] Most feedback-regulated systems utilize **negative feedback**, where an increase in the physiological marker triggers drug release, and normalization of the marker suppresses further release. This self-limiting behavior prevents excessive drug administration and mimics natural endocrine and metabolic regulation processes.^[38-43]

3.3 Types of Feedback Control Mechanisms

3.3.1 Negative Feedback Control

Negative feedback is the most widely employed mechanism in feedback-regulated drug delivery. In this approach, drug release is proportional to the deviation of a biomarker from its target value. Once the therapeutic goal is achieved, further drug release is automatically reduced or stopped. Glucose-responsive insulin delivery systems are a classic example of negative feedback control.^[38-43,51-55]

3.3.2 Positive Feedback Control

Positive feedback mechanisms amplify the response when a specific stimulus is detected. Although less common in drug delivery due to the risk of uncontrolled release, positive feedback may be useful in applications requiring rapid drug release, such as acute pain or emergency interventions.^[38,40,45]

3.3.3 On–Off (Threshold-Based) Control

In on–off control systems, drug release is initiated only when the physiological parameter crosses a predefined threshold. Once the parameter returns to the acceptable range, drug release ceases. These systems are relatively simple to design and are commonly used in stimulus-responsive polymeric systems.^[13,38-40]

3.3.4 Proportional–Integral–Derivative (PID) Control

PID control strategies integrate proportional, integral, and derivative responses to achieve precise regulation of drug release. Although more complex, PID-based systems offer superior stability and accuracy and are increasingly explored in bioelectronic and digitally controlled drug delivery platforms.^[1,14,25,51-53]

3.4 Physiological and Biochemical Stimuli Used for Feedback Regulation

Feedback-regulated drug delivery systems rely on specific internal stimuli that reflect disease state or therapeutic response.^[38-49] Commonly used stimuli include:

- **Glucose concentration:** Widely used in diabetes management.^[39-44,51-55]
- **pH variations:** Exploited in tumor microenvironments and inflammatory conditions.^[45,48,49]
- **Enzymatic activity:** Used for site-specific drug release.^[44,47]
- **Inflammatory biomarkers:** Enable targeted therapy in autoimmune and inflammatory diseases.^[23,35-37]
- **Hormone levels:** Applied in endocrine disorder management.^[1,2,51-53]

The selection of an appropriate stimulus is critical to ensure accurate feedback and reliable therapeutic control.

Table 1: Physiological Stimuli Used in Feedback-Regulated Drug Delivery Systems.^[39,40,42,44,45,47-49]

Stimulus	Biological Source	Mechanism of Drug Release	Therapeutic Application
Glucose	Blood glucose fluctuations	Enzyme-triggered insulin release	Diabetes mellitus
pH changes	Tumor microenvironment or inflamed tissue	pH-sensitive polymer swelling or degradation	Cancer therapy
Enzymatic activity	Disease-specific enzymes	Enzyme-mediated cleavage of carrier materials	Targeted anticancer drug delivery
Reactive oxygen species (ROS)	Inflammatory conditions	Oxidation-responsive polymers	Anti-inflammatory therapy
Hormone levels	Endocrine system fluctuations	Hormone-responsive materials	Hormonal disorders
Neural signals	Electrical activity in nervous system	Neural-triggered drug release	Neurological disorders




Figure 1: Schematic representation of the concept of feedback-regulated drug delivery systems. Disease-related physiological changes generate a biochemical stimulus that is detected by responsive sensors integrated within the drug carrier. This stimulus triggers-controlled drug release through a rate-controlling element. The released drug restores the physiological state toward normal, and the resulting change in the biomarker provides feedback to modulate further drug release, thereby forming a self-regulating closed-loop system.^[1,13,38-40]

3.5 Materials Used in Feedback-Regulated Drug Delivery Systems

The functionality of feedback-regulated systems depends heavily on the materials used for sensing and drug release. Common materials include:

- **Stimuli-responsive polymers:** Undergo physical or chemical changes in response to specific stimuli.^[45,48,49]
- **Hydrogels:** Capable of swelling or shrinking in response to environmental changes.^[45]
- **Nanoparticles:** Enable rapid response and high surface area interactions.^[13,38-44,49]
- **Biomolecule-based carriers:** Utilize enzymes, antibodies, or aptamers for specific recognition.^[39,40,44,47]

These materials are designed to ensure biocompatibility, stability, and reproducibility of response.

3.6 Design Strategies for Feedback-Regulated Drug Delivery

Designing feedback-regulated drug delivery systems requires careful integration of sensing, response, and drug release components. Key design considerations include:

- Sensitivity and specificity of the sensing mechanism
- Response time of the system
- Stability of feedback control
- Reversibility of stimulus-responsive behavior
- Compatibility with the drug and physiological environment.^[1,11,13-16]

Effective design ensures consistent therapeutic outcomes and long-term functionality.

3.7 Examples of Feedback-Regulated Drug Delivery Systems

One of the most extensively studied examples is **glucose-responsive insulin delivery**, where insulin release is regulated by glucose levels using enzymatic or polymeric sensors.^[39-43,51-55] Other notable examples include enzyme-triggered anticancer drug delivery systems and inflammation-responsive corticosteroid release platforms.^[44,47] These systems demonstrate the potential of feedback-regulated drug delivery to achieve precise, self-adjusting therapeutic control.

4. Bioelectronic Drug Delivery Systems

Bioelectronic drug delivery systems represent a rapidly emerging interdisciplinary field that integrates principles of electronics, biology, and pharmaceutical sciences to achieve precise therapeutic modulation.^[3-10] These systems utilize electronic components to sense physiological signals, process biological information, and control drug release in a highly accurate and programmable manner. By interfacing directly with biological pathways, bioelectronic drug delivery systems enable real-time, patient-specific therapeutic intervention and form a critical foundation for closed-loop therapeutics.^[3,7,10-14]

4.1 Concept of Bioelectronic Medicine

Bioelectronic medicine involves the use of electronic devices to monitor and modulate biological processes for therapeutic purposes.^[3-9,23,24] Unlike conventional pharmacotherapy, which relies solely on chemical interactions, bioelectronic approaches exploit electrical signals inherent to physiological systems such as neural pathways, cardiac rhythms, and endocrine signaling. In drug delivery applications, bioelectronics serve as an interface between biological signals and controlled drug administration.^[23,28-37] By translating physiological inputs into electronic signals and subsequently regulating drug release, bioelectronic systems enable precise control over therapeutic dosing. This approach allows for rapid response to physiological changes and significantly reduces the reliance on fixed dosing schedules.

4.2 Evolution of Bioelectronics in Drug Delivery

The evolution of bioelectronic drug delivery systems has been driven by advancements in microelectronics, biosensor technology, microfabrication, and wireless communication.^[6,9-12,15,18] Early electronic drug delivery devices were limited by size, power requirements, and lack of biocompatibility. However, recent developments in flexible electronics, implantable sensors, and low-power integrated circuits have enabled the design of compact, reliable, and long-lasting bioelectronic platforms.^[6,9,15-18] The convergence of nanotechnology and bioelectronics has further enhanced the sensitivity and specificity of biosensors, allowing continuous monitoring of biomarkers at clinically

relevant concentrations. These advancements have transformed bioelectronic drug delivery from a conceptual innovation into a clinically viable therapeutic strategy.

4.3 Components of Bioelectronic Drug Delivery Systems

Bioelectronic drug delivery systems consist of multiple integrated components that function cohesively to achieve controlled therapeutic outcomes.

4.3.1 Biosensors

Biosensors are responsible for detecting physiological or biochemical signals associated with disease states or therapeutic responses. These sensors may be electrochemical, optical, or electrical in nature and are designed to measure parameters such as glucose levels, neurotransmitter concentrations, inflammatory biomarkers, or electrophysiological signals. High sensitivity, selectivity, and long-term stability are essential for reliable performance.^[10-15,35,39]

4.3.2 Signal Processing and Control Units

The signal processing unit converts sensor output into a digital format and analyzes the data using embedded algorithms. These control units determine the appropriate therapeutic response by comparing real-time data with predefined target values. Advanced systems employ adaptive algorithms that learn from patient-specific responses to optimize dosing accuracy.^[1,9,14,25,51-53]

4.3.3 Drug Reservoir and Release Mechanism

The drug reservoir stores the therapeutic agent and is connected to a controlled release mechanism. Drug release may be achieved using micro-pumps, electrochemical actuation, membrane permeability modulation, or electrically responsive materials. These mechanisms ensure precise, repeatable, and timely drug administration.^[12-14,18,25]

4.3.4 Power Supply and Communication Modules

Bioelectronic systems require reliable power sources, such as micro-batteries, wireless power transfer, or energy-harvesting technologies. Communication modules enable data transmission to external devices, allowing remote monitoring, data analysis, and system adjustments.^[6,9,15,18,29,30]

4.4 Types of Bioelectronic Drug Delivery Systems

Bioelectronic drug delivery systems can be classified based on their mode of application and level of invasiveness.

4.4.1 Implantable Bioelectronic Systems

Implantable systems are surgically placed within the body and provide long-term therapeutic control. These systems are commonly used for chronic disease management and allow continuous monitoring and drug delivery with minimal patient intervention. Biocompatibility and long-term stability are critical considerations for implantable devices.^[6,10-12,16,18,19]

4.4.2 Wearable Bioelectronic Systems

Wearable systems are non-invasive or minimally invasive devices designed for external application. They offer flexibility, ease of use, and patient comfort. Wearable bioelectronic drug delivery systems are particularly suitable for transdermal drug administration and real-time physiological monitoring.^[14-17]

4.4.3 Ingestible Bioelectronic Devices

Ingestible devices are designed to be swallowed and operate within the gastrointestinal tract. These systems enable site-specific drug delivery and real-time monitoring of gastrointestinal conditions. After completing their function, the devices are safely excreted from the body.^[1,14,18,19]

4.4.4 Neural-Controlled Drug Delivery Systems

Neural-controlled systems interface directly with the nervous system to regulate drug delivery based on neural signals. These systems are particularly relevant in neurological disorders, pain management, and inflammatory diseases, where neural pathways play a critical role in disease modulation.^[20-25,28-37]

4.5 Mechanisms of Drug Release in Bioelectronic Systems

Bioelectronic drug delivery systems employ various mechanisms to achieve controlled drug release. Electrical stimulation can trigger drug release by altering membrane permeability, activating electrochemical reactions, or controlling microfluidic pumps. These mechanisms allow rapid and precise control over drug dosing, making bioelectronic systems highly responsive to physiological changes.^[18,25,29-33]

4.6 Applications of Bioelectronic Drug Delivery Systems

Bioelectronic drug delivery systems have demonstrated significant potential across a wide range of therapeutic areas. In diabetes management, bioelectronic systems enable automated insulin delivery based on continuous glucose monitoring.^[2,39-43,51-55] In neurological disorders, they facilitate targeted delivery of neuroactive agents while minimizing systemic exposure.^[20-25,28-37] These systems are also being explored for cardiovascular diseases, inflammatory conditions, and cancer therapy.^[23,28,35-37,44,47]

5. Integration of Feedback Regulation with Bioelectronic DDS

The integration of feedback regulation with bioelectronic drug delivery systems represents a critical advancement toward the realization of true closed-loop therapeutics.^[1,3,10,13,14] While feedback-regulated drug delivery systems provide autonomous responsiveness to physiological stimuli, and bioelectronic systems offer precise sensing and programmable control, their integration enables continuous, real-time therapeutic modulation with high accuracy and adaptability. This synergistic approach bridges biological feedback mechanisms with electronic decision-making, resulting in intelligent drug delivery platforms capable of maintaining physiological homeostasis.^[1,9,13,14]




Figure 2: Schematic representation of a closed-loop bioelectronic drug delivery system.

The system integrates biosensors, signal processing units, control algorithms, and drug delivery actuators to enable automated therapeutic regulation. Biosensors continuously detect physiological biomarkers such as glucose, pH, or inflammatory cytokines and transmit signals to a processing unit for data analysis. The processed information is interpreted by control algorithms that determine the appropriate therapeutic dose. Based on this decision, the actuator or micro-pump releases the drug from the reservoir into the patient. The resulting physiological response is continuously monitored, creating a feedback loop that allows dynamic adjustment of drug delivery and maintenance of physiological homeostasis.^[1,10,13,14]

5.1 Sensor-Based Real-Time Physiological Monitoring

At the core of integrated closed-loop bioelectronic systems lies continuous physiological monitoring.^[10-15] Biosensors embedded within or attached to the delivery platform detect disease-relevant biomarkers such as glucose levels, inflammatory mediators, neurotransmitters, hormones, or electrophysiological signals.^[11,15,23,35,39] These sensors convert biological inputs into electrical signals that reflect the patient's real-time physiological state. The accuracy and reliability of sensor data are essential for effective feedback regulation. Advanced biosensors are designed to exhibit high sensitivity, specificity, minimal signal drift, and long-term stability within complex biological environments. Continuous monitoring enables early detection of physiological deviations, allowing the system to respond before clinically significant deterioration occurs.^[6,11,15,16]

5.2 Signal Processing and Control Algorithms

Once physiological signals are detected, they are processed by embedded electronic control units. Signal processing involves amplification, filtering, and digitization to ensure accurate interpretation of biological inputs.^[10,14,18,25] These processed signals are then analyzed using control algorithms that determine the magnitude and timing of drug release required to restore or maintain therapeutic targets. Control algorithms in integrated systems range from simple threshold-based logic to advanced adaptive and predictive models.^[1,14,25,51-53] Proportional–integral–derivative (PID) controllers are commonly employed to ensure stability and minimize oscillations in drug concentration.^[1,25,51-53] More sophisticated systems incorporate machine learning and artificial intelligence-based algorithms capable of learning from patient-specific responses and adapting dosing strategies over time.^[1,9,25,51-53]

5.3 Automated and Programmable Drug Release Mechanisms

The integration of feedback regulation with bioelectronics enables automated and programmable drug release. Once the control algorithm determines the required therapeutic action, electronic actuators initiate drug release from the reservoir. Drug delivery may be achieved using micro-pumps, electrochemical stimulation, electrically responsive membranes, or microfluidic channels. These electronically controlled release mechanisms offer precise control over dose, rate, and timing of drug administration. The ability to modulate drug delivery dynamically allows the system to respond rapidly to physiological fluctuations, thereby reducing the risk of under- or over-medication.^[12-14,18,25]

Integrated feedback-regulated bioelectronic systems operate as closed-loop platforms, where sensing, decision-making, and actuation occur continuously and autonomously. These platforms are designed to function with minimal patient intervention, enhancing convenience and compliance. A prominent example is automated insulin delivery systems, commonly referred to as artificial pancreas devices. These systems continuously monitor glucose levels and adjust insulin delivery in real time. Similar platforms are being developed for neurological disorders, where neural signals

guide the delivery of neuroactive drugs, and for inflammatory diseases, where biomarker levels regulate anti-inflammatory drug release.^[1, 2, 7, 20, 23, 25, 28, 35–37, 39–43, 51–55]

5.5 Synchronization of Biological and Electronic Feedback Loops

Successful integration requires precise synchronization between biological feedback mechanisms and electronic control loops. Biological systems often exhibit nonlinear and time-dependent responses, which must be accurately modeled and incorporated into electronic control strategies. Delays in sensing, signal processing, or drug release can destabilize the system and compromise therapeutic efficacy. To address this challenge, integrated systems are designed with high-speed sensors, low-latency electronics, and predictive algorithms that anticipate physiological trends. This synchronization ensures smooth and stable therapeutic regulation.^[1,9,14,25,51-53]

5.6 Personalization and Adaptive Therapeutic Control

One of the most significant advantages of integrating feedback regulation with bioelectronic DDS is the ability to personalize therapy. Individual patients exhibit variability in pharmacokinetics, pharmacodynamics, and disease progression. Integrated closed-loop systems adapt to these variations by continuously updating control parameters based on real-time patient data. Adaptive control strategies allow the system to refine dosing regimens over time, improving therapeutic outcomes and minimizing adverse effects. This personalization aligns closely with the principles of precision medicine.^[1,14,27,51-53]

5.7 Safety, Reliability, and Fail-Safe Mechanisms

Integrated bioelectronic drug delivery systems are designed with multiple safety features to ensure reliable operation. Fail-safe mechanisms include redundant sensors, error detection algorithms, and emergency shutdown protocols to prevent uncontrolled drug release. Continuous system diagnostics and real-time data monitoring further enhance safety and reliability. Such safeguards are essential for clinical acceptance and regulatory approval of closed-loop bioelectronic therapeutics.^[6,9,10,15,16]

6. Applications of Closed-Loop Bioelectronic Drug Delivery Systems

Closed-loop bioelectronic drug delivery systems have demonstrated significant potential across a wide range of therapeutic areas, particularly in diseases that require continuous monitoring, precise dose adjustment, and long-term management. By integrating real-time biosensing, feedback regulation, and automated drug delivery, these systems enable personalized and adaptive therapy, thereby improving clinical outcomes and reducing treatment-related complications.^[1,3,7,14,20,23,51-53]

Table 2: Clinical Applications of Closed-Loop Bioelectronic Drug Delivery Systems.^[2,20,23,25,28,35-37,39-44,51-55]

Disease	Biomarker Monitored	Drug Delivered	Closed-Loop Strategy
Diabetes mellitus	Blood glucose	Insulin	Artificial pancreas systems
Parkinson's disease	Neural activity	Dopaminergic agents	Neural-controlled drug delivery
Hypertension	Blood pressure	Antihypertensive drugs	Sensor-controlled drug infusion
Chronic pain	Neural signals	Analgesics	Neuromodulation-guided drug release
Cancer	Tumor biomarkers / pH	Chemotherapeutic agents	Biomarker-triggered drug delivery
Inflammatory diseases	Cytokines / inflammatory markers	Anti-inflammatory drugs	Inflammation-responsive DDS

6.1 Diabetes Mellitus Management

Diabetes mellitus represents the most advanced and clinically validated application of closed-loop bioelectronic drug delivery systems.^[2,39-43,51-55] In this context, continuous glucose monitoring sensors measure interstitial glucose levels in real time, and control algorithms dynamically adjust insulin delivery to maintain euglycemia.^[2,39-43,51-55] Automated insulin delivery systems, often referred to as artificial pancreas systems, exemplify the successful integration of biosensors, electronic controllers, and insulin infusion devices.^[2,51-55] These systems significantly reduce glycemic variability, lower the risk of hypoglycemia, and improve overall metabolic control. The closed-loop approach minimizes patient dependence on frequent glucose measurements and manual insulin dosing, thereby enhancing quality of life and long-term disease management.^[51-55]

6.2 Neurological Disorders

Neurological disorders such as epilepsy, Parkinson's disease, depression, and chronic pain are characterized by complex and fluctuating neural activity. Closed-loop bioelectronic drug delivery systems enable real-time monitoring of neural signals and provide targeted delivery of neuroactive agents in response to abnormal electrical activity.^[20-22] In epilepsy management, neural sensors detect seizure-related electrical patterns and trigger the release of antiepileptic drugs or initiate neuromodulation to suppress seizure activity. Similarly, in Parkinson's disease, closed-loop systems can adjust dopaminergic drug delivery based on neural feedback, reducing motor fluctuations and dyskinesia. These approaches improve therapeutic precision while minimizing systemic drug exposure and associated side effects.^[25,28-37]

6.3 cardiovascular diseases

Cardiovascular disorders such as hypertension, arrhythmias, and heart failure require tight regulation of physiological parameters. Closed-loop bioelectronic drug delivery systems can continuously monitor cardiovascular signals, including blood pressure, heart rate, and electrophysiological activity, and adjust drug delivery accordingly. For example, antihypertensive drug delivery can be modulated based on real-time blood pressure readings, preventing episodes of hypotension or uncontrolled hypertension. In arrhythmia management, bioelectronic systems can integrate sensing and therapeutic intervention to deliver antiarrhythmic drugs or electrical stimulation when abnormal cardiac rhythms are detected. Such systems offer improved cardiovascular stability and reduced risk of adverse events.^[23,29,30,35]

6.4 Chronic Pain Management

Chronic pain management presents significant challenges due to variability in pain perception, tolerance, and disease progression. Closed-loop bioelectronic drug delivery systems enable adaptive pain management by integrating neural or physiological feedback with controlled drug administration. These systems can monitor neural activity or biomarkers associated with pain and modulate the release of analgesics accordingly. By delivering drugs only when required and at optimal doses, closed-loop systems reduce the risk of drug tolerance, dependency, and systemic side effects. This approach is particularly valuable in long-term pain conditions where conventional dosing often leads to suboptimal outcomes.^[23,25,28-30,33,34]

6.5 Cancer Therapy

Cancer therapy often requires precise control over drug dosing to maximize tumor suppression while minimizing toxicity to healthy tissues. Closed-loop bioelectronic drug delivery systems can respond to tumor-specific biomarkers, microenvironmental changes such as pH or enzymatic activity, and treatment response indicators. By dynamically adjusting chemotherapeutic drug delivery based on real-time feedback, these systems can improve therapeutic efficacy

and reduce adverse effects. Additionally, closed-loop platforms may enable localized and site-specific drug release, enhancing drug accumulation at the tumor site and reducing systemic exposure.^[44,47-49]

6.6 Inflammatory and Autoimmune Disorders

Inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, involve fluctuating inflammatory activity that is difficult to manage with fixed dosing regimens. Closed-loop bioelectronic drug delivery systems can monitor inflammatory biomarkers and regulate the release of anti-inflammatory or immunomodulatory agents accordingly. This adaptive approach ensures timely intervention during disease flares while minimizing drug exposure during remission periods. As a result, closed-loop systems reduce long-term drug toxicity and improve disease control.^[23,35-37]

6.7 Hormonal and Metabolic Disorders

Hormonal disorders such as thyroid dysfunction, adrenal insufficiency, and growth hormone deficiency require careful dose titration to maintain physiological balance. Closed-loop bioelectronic drug delivery systems enable real-time monitoring of hormone levels and adjust replacement therapy accordingly. By maintaining hormone concentrations within narrow physiological ranges, these systems improve metabolic stability, reduce side effects, and enhance patient adherence to therapy. This application underscores the broader potential of closed-loop systems in endocrine and metabolic disease management.^[1,2,42,51-53]

7. Challenges and Limitations

Despite the significant promise of closed-loop bioelectronic therapeutic systems, several scientific, technological, clinical, regulatory, and ethical challenges hinder their widespread clinical translation. Addressing these limitations is essential for ensuring safety, reliability, and long-term therapeutic success.^[1,6,9-16]

7.1 Biocompatibility and Long-Term Safety

One of the foremost challenges in closed-loop bioelectronic systems is ensuring long-term biocompatibility of implanted or wearable components. Continuous interaction between electronic materials and biological tissues may induce inflammatory responses, fibrosis, or device encapsulation, leading to reduced sensor sensitivity and impaired drug delivery.^[6,15,16,18] Chronic implantation also raises concerns related to material degradation, corrosion, and release of potentially toxic by-products. Ensuring stable and inert material interfaces over extended periods remains a critical limitation.^[6,15,16]

7.2 Sensor Accuracy, Stability, and Signal Drift

Closed-loop systems rely heavily on accurate and reliable biosensing. Sensor drift, biofouling, and loss of sensitivity over time can compromise the accuracy of physiological measurements. Even minor inaccuracies in sensor readings can lead to inappropriate drug dosing, resulting in therapeutic failure or adverse effects. Maintaining long-term sensor calibration in complex biological environments remains a major technical challenge, particularly for implantable devices.^[1,6,11,15,16]

7.3 Latency and System Responsiveness

Delays in sensing, signal processing, algorithmic decision-making, or drug release can destabilize closed-loop systems. Physiological processes often change rapidly, and delayed therapeutic responses may reduce system effectiveness or

exacerbate disease conditions. Ensuring low-latency communication and rapid actuation while maintaining system stability is a significant engineering and pharmaceutical challenge.^[1,9,14,25,51-53]

7.4 Power Supply and Energy Management

Bioelectronic drug delivery systems require reliable power sources to operate sensors, processors, and actuators. Limited battery life, frequent recharging, or surgical replacement of power units pose practical and safety concerns, particularly for implantable systems. Although wireless power transfer and energy-harvesting technologies show promise, their integration into safe, efficient, and miniaturized therapeutic platforms remains challenging.^[6,9,15,18,29,30]

7.5 Device Miniaturization and System Integration

The integration of multiple components-sensors, processors, drug reservoirs, actuators, and communication modules into a compact and patient-friendly device is technically complex. Miniaturization must be achieved without compromising performance, durability, or safety. Design trade-offs between size, functionality, and reliability continue to limit the scalability and clinical applicability of closed-loop systems.^[6,9,15,18]

7.6 Drug Stability and Reservoir Limitations

Long-term storage of drugs within bioelectronic delivery systems poses challenges related to drug stability, degradation, and compatibility with device materials. Maintaining drug potency over extended periods is critical for chronic therapeutic applications. Additionally, limited reservoir capacity necessitates periodic refilling or device replacement, which may increase patient burden and risk of infection.^[1,12-14,18,19]

7.7 Algorithm Reliability and Personalization Challenges

Control algorithms form the decision-making core of closed-loop systems. Developing algorithms that are robust, adaptive, and safe across diverse patient populations is challenging. Individual variability in disease progression, pharmacokinetics, and pharmacodynamics complicates algorithm design. Over-reliance on automated decision-making also raises concerns regarding algorithm errors, unintended interactions, and system failure under atypical physiological conditions.^[1,9,14,25,51-53]

7.8 Data Security and Privacy Concerns

Closed-loop bioelectronic systems often involve continuous data collection, storage, and wireless transmission of sensitive health information. Ensuring data security and patient privacy is a critical challenge, particularly in remotely monitored or cloud-connected systems. Unauthorized access, data breaches, or cyberattacks could compromise patient safety and undermine trust in these technologies.^[3,9,14]

7.9 Regulatory and Approval Challenges

Closed-loop bioelectronic drug delivery systems are typically classified as combination products involving drugs, devices, and software. Navigating complex regulatory pathways and meeting stringent safety and efficacy requirements is a major barrier to clinical adoption. The lack of standardized regulatory frameworks for adaptive and autonomous therapeutic systems further complicates approval processes and delays commercialization.^[1,3,6,9,51]

7.10 Ethical and Societal Considerations

The autonomous nature of closed-loop systems raises ethical concerns related to patient autonomy, informed consent, and long-term dependence on automated therapy. Patients may have limited control or understanding of algorithm-

driven treatment decisions. Additionally, high development and implementation costs may limit accessibility, raising concerns about healthcare equity and disparity.^[3-5,7,9,23]

7.11 Clinical Validation and Real-World Implementation

While many closed-loop systems show promising results in controlled laboratory and clinical trial settings, translating these outcomes into real-world clinical practice remains challenging. Variability in patient behavior, environmental factors, and healthcare infrastructure can affect system performance. Large-scale, long-term clinical studies are required to validate safety, effectiveness, and cost-benefit profiles before widespread adoption.^[1,2,9,51-55]

8. Regulatory and Ethical Considerations

The clinical translation of closed-loop bioelectronic drug delivery systems is governed by complex regulatory and ethical frameworks due to their hybrid nature, combining pharmaceuticals, medical devices, and software-driven control algorithms. While these systems offer transformative potential for personalized therapy, their approval and adoption require careful evaluation of safety, efficacy, reliability, and ethical implications.^[1,3,6,9,51]

8.1 Regulatory Classification of Closed-Loop Bioelectronic Systems

Closed-loop bioelectronic drug delivery systems are typically classified as **combination products**, as they integrate three major components:

1. A **drug or biologic**,
2. A **medical device** (sensor, actuator, implant, or wearable), and
3. **Software or algorithms** that control therapeutic decision-making.^[1,6,9,51]

This multi-component nature complicates regulatory pathways, as each component must meet distinct regulatory standards while also demonstrating safety and effectiveness as an integrated system. Regulatory authorities such as the Central Drugs Standard Control Organisation and the U.S. Food and Drug Administration require coordinated evaluation across pharmaceutical, medical device, and digital health divisions.

8.2 Preclinical and Clinical Evaluation Requirements

Before clinical approval, closed-loop systems must undergo extensive **preclinical testing**, including:

- Biocompatibility and toxicity studies
- Device durability and mechanical stability
- Sensor accuracy and reliability
- Drug stability within delivery reservoirs
- Validation of feedback algorithms

Clinical evaluation poses additional challenges, as these systems must demonstrate not only therapeutic efficacy but also long-term safety and system reliability. Clinical trials must assess performance under real-world conditions, including patient variability, disease fluctuations, and device malfunction scenarios.^[1,6,9,11,15,16,51-55]

8.3 Validation of Control Algorithms and Software

Control algorithms play a central role in closed-loop therapeutic systems, as they autonomously determine drug dosing and timing. Regulatory agencies require rigorous validation of software performance, including:

- Algorithm accuracy and robustness
- Fail-safe mechanisms and error handling
- Cybersecurity safeguards
- Update and version control procedures

Adaptive or learning algorithms present additional regulatory challenges, as their behavior may evolve over time. Regulators must ensure that algorithmic adaptation does not compromise patient safety or therapeutic consistency.^[1,9,14,25,51-53]

8.4 Safety, Risk Management, and Fail-Safe Design

Closed-loop systems must incorporate comprehensive risk management strategies to address potential system failures. Regulatory guidelines emphasize the need for:

- Redundant sensing mechanisms
- Emergency shutdown protocols
- Manual override options
- Continuous system diagnostics

These safety measures are essential to prevent uncontrolled drug delivery and to ensure patient protection in the event of hardware, software, or communication failures.^[1,6,9,10,25]

8.5 Ethical Considerations in Autonomous Therapeutic Systems

The autonomous operation of closed-loop bioelectronic systems raises important ethical questions. One major concern is **patient autonomy**, as treatment decisions are partially delegated to automated algorithms. Ensuring that patients understand how the system functions and how decisions are made is critical for ethical clinical practice. **Informed consent** must explicitly address the automated nature of therapy, potential risks, data usage, and system limitations. Patients should retain the right to override or discontinue automated treatment when necessary.^[3-5,7,9,23]

8.6 Data Privacy and Confidentiality

Closed-loop bioelectronic systems often involve continuous data collection and wireless data transmission for monitoring and optimization. This creates ethical and legal responsibilities related to patient data protection. Ensuring confidentiality, secure data storage, and protection against unauthorized access is essential. Compliance with national and international data protection regulations is mandatory to maintain patient trust and safeguard sensitive health information.^[3,9,14]

8.7 Long-Term Implantation and Patient Safety

Implantable bioelectronic drug delivery systems raise ethical concerns related to long-term implantation, including device explantation, replacement procedures, and long-term health effects. Ethical evaluation must consider the balance between therapeutic benefit and potential risks associated with chronic implantation. Regular post-marketing surveillance and long-term follow-up studies are ethically necessary to monitor safety and effectiveness over time.^[6,11,16,18,19]

8.8 Equity, Accessibility, and Cost Considerations

The advanced technology and high development costs associated with closed-loop bioelectronic systems may limit their accessibility, particularly in low- and middle-income settings. Ethical concerns arise regarding equitable access to these therapies and the potential widening of healthcare disparities. Strategies to reduce manufacturing costs, simplify device design, and ensure affordability are essential for ethical and inclusive healthcare implementation.^[1,3,4,9,27]

8.9 Regulatory Harmonization and Global Challenges

Differences in regulatory requirements across countries can delay global adoption of closed-loop bioelectronic therapies. Harmonization of standards for combination products, digital therapeutics, and bioelectronic devices is necessary to streamline approval processes and encourage innovation. International collaboration among regulatory agencies, academic institutions, and industry stakeholders will play a critical role in shaping consistent regulatory frameworks.^[1,3,6,9,51]

9. Future Perspectives and Emerging Trends

The future of closed-loop bioelectronic drug delivery systems lies at the convergence of pharmaceutical sciences, bioelectronics, data science, and digital health. Rapid technological advancements and growing clinical demand for personalized therapy are driving the evolution of intelligent, adaptive, and patient-centric therapeutic platforms. Emerging trends suggest that closed-loop systems will move beyond disease-specific applications toward integrated, multi-modal precision medicine solutions.^[1,3,4,6,9,14,51]

9.1 Artificial Intelligence–Driven Closed-Loop Therapeutics

Artificial intelligence (AI) is expected to play a transformative role in the next generation of closed-loop drug delivery systems. Unlike conventional rule-based control algorithms, AI-driven systems can analyze complex physiological datasets, recognize hidden patterns, and predict therapeutic needs before clinical deterioration occurs. Machine learning models trained on patient-specific data can continuously optimize dosing strategies, reduce therapeutic lag, and improve long-term disease control. AI integration will enable predictive and preventive therapy, shifting healthcare from reactive to proactive disease management.^[1,9,25,51]

9.2 Adaptive and Self-Learning Control Algorithms

Future closed-loop systems are likely to employ adaptive and self-learning algorithms that evolve in response to patient-specific pharmacokinetics, pharmacodynamics, and disease progression. These systems will refine control parameters over time, ensuring sustained therapeutic accuracy even in the presence of physiological changes such as aging, lifestyle modifications, or disease remission and relapse. Self-learning systems will reduce the need for frequent clinical recalibration and improve long-term system reliability.^[1,9,14,25,51-53]

9.3 Digital Twin Technology in Drug Delivery

Digital twin technology, which involves creating a virtual representation of a patient's physiological system, represents a promising trend in closed-loop therapeutics. By simulating disease progression and therapeutic response, digital twins can support real-time decision-making and dose optimization. Integration of digital twins with closed-loop bioelectronic systems may allow clinicians to test therapeutic strategies virtually before applying them in vivo, thereby reducing risks and improving treatment precision.^[56]

10. CONCLUSION

Closed-loop bioelectronic drug delivery systems represent a transformative advancement in modern pharmacotherapy, offering a shift from conventional fixed-dose regimens toward intelligent, adaptive, and patient-specific therapeutic strategies.^[1,3,7,51] By integrating real-time biosensing, feedback regulation, and electronically controlled drug delivery, these systems closely emulate physiological homeostasis and enable precise modulation of therapeutic interventions^[1,10,13,14]. Feedback-regulated drug delivery systems provide the foundational principle of autonomous responsiveness, while bioelectronic platforms offer the technological capability for accurate sensing, programmable control, and reliable actuation.^[13,38-40] Their integration results in closed-loop therapeutics capable of continuous disease monitoring, dynamic dose adjustment, and sustained therapeutic stability.^[1,10,13,14,51] This approach has demonstrated particular promise in chronic disease management, including diabetes mellitus, neurological disorders, cardiovascular diseases, inflammatory conditions, and hormonal imbalances.^[2,20,23,39-43,51-55] Despite their considerable potential, several challenges related to biocompatibility, sensor stability, power management, algorithm validation, regulatory complexity, and ethical considerations must be addressed to ensure safe and effective clinical translation.^[6,9,11,15,16,25,51] Continued interdisciplinary collaboration among pharmaceutical scientists, biomedical engineers, clinicians, and regulatory authorities will be essential to overcome these barriers.^[3-6,9] Future developments in artificial intelligence, adaptive control algorithms, miniaturized bioelectronics, and digital health integration are expected to further enhance the performance and accessibility of closed-loop therapeutic systems.^[1,6,9,14,25,51] As these technologies mature, closed-loop bioelectronic drug delivery systems are poised to play a pivotal role in advancing precision medicine, improving patient outcomes, and redefining the future landscape of drug delivery and therapeutic management.^[1,3,4,7,51-53]

REFERENCES

1. Paci MM, Saha T, Djassemi O, Wu S, Chua CYX, Wang J, et al. Smart closed-loop drug delivery systems. *Nat Rev Bioeng*, 2025; 3: 816-834. doi:10.1038/s44222-025-00328-z.
2. Ware J, Hovorka R. Closed-loop insulin delivery: update on the state of the field and emerging technologies. *Expert Rev Med Devices*, 2022; 19(11): 859-875. doi:10.1080/17434440.2022.2142556.
3. Koutsouras DA, Malliaras GG, Langereis G. The rise of bioelectronic medicine. *Bioelectron Med*, 2024; 10: 19. doi:10.1186/s42234-024-00151-8.
4. Das S, Ghosh B, Sahoo RN, Nayak AK. Recent advancements in bioelectronic medicine: a review. *Curr Drug Deliv*, 2024; 21(11): 1445-1459. doi:10.2174/0115672018286832231218112557.
5. González-González MA, Conde SV, Latorre R, Thébault SC, Pratelli M, Spitzer NC, et al. Bioelectronic medicine: a multidisciplinary roadmap from biophysics to precision therapies. *Front Integr Neurosci*, 2024; 18: 1321872. doi:10.3389/fnint.2024.1321872.
6. Oldroyd P, El Hadwe S, Barone DG, Malliaras GG. Thin-film implants for bioelectronic medicine. *MRS Bull*, 2024; 49(10): 1045-1058. doi:10.1557/s43577-024-00786-7.
7. Pavlov VA, Tracey KJ. Bioelectronic medicine: preclinical insights and clinical advances. *Neuron*, 2022; 110(21): 3627-3644. doi: 10.1016/j.neuron.2022.09.003.
8. Birmingham K, Gradinaru V, Anikeeva P, Grill WM, Pikov V, McLaughlin B, et al. Bioelectronic medicines: a research roadmap. *Nat Rev Drug Discov*, 2014; 13(6): 399-400. doi:10.1038/nrd4351.
9. Baldwin A, States G, Pikov V, Gunalan P, Elyahoodayan S, Kilgore K, et al. Recent advances in facilitating the translation of bioelectronic medicine therapies. *Curr Opin Biomed Eng*, 2025; 33: 100575. doi: 10.1016/j.cobme.2024.100575.

10. Bhave G, Chen JC, Singer A, Sharma A, Robinson JT. Distributed sensor and actuator networks for closed-loop bioelectronic medicine. *Mater Today*, 2021; 46: 125-135. doi: 10.1016/j.mattod.2020.12.020.
11. Scholten K, Meng E. A review of implantable biosensors for closed-loop glucose control and other drug delivery applications. *Int J Pharm*, 2018; 544(2): 319-334. doi: 10.1016/j.ijpharm.2018.02.022.
12. Coffel J, Nuxoll E. BioMEMS for biosensors and closed-loop drug delivery. *Int J Pharm*, 2018; 544(2): 335-349. doi: 10.1016/j.ijpharm.2018.01.030.
13. Yu J, Zhang Y, Yan J, Kahkoska AR, Gu Z. Advances in bioresponsive closed-loop drug delivery systems. *Int J Pharm*, 2018; 544(2): 350-357. doi: 10.1016/j.ijpharm.2017.11.064.
14. Manikkath J, Subramony JA. Toward closed-loop drug delivery: integrating wearable technologies with transdermal drug delivery systems. *Adv Drug Deliv Rev*, 2021; 179: 113997. doi: 10.1016/j.addr.2021.113997.
15. Zheng Z, Zhu R, Peng I, Xu Z, Jiang Y. Wearable and implantable biosensors: mechanisms and applications in closed-loop therapeutic systems. *J Mater Chem B*, 2024; 12(35): 8577-8604. doi:10.1039/D4TB00782D.
16. Kar A, Ahamad N, Dewani M, Awasthi L, Patil R, Banerjee R. Wearable and implantable devices for drug delivery: applications and challenges. *Biomaterials*, 2022; 283: 121435. doi: 10.1016/j.biomaterials.2022.121435.
17. Khadka B, Lee B, Kim KT. Drug delivery systems for personal healthcare by smart wearable patch system. *Biomolecules*, 2023; 13(6): 929. doi:10.3390/biom13060929.
18. Jiang X, Wu H, Xiao A, Huang Y, Yu X, Chang L. Recent advances in bioelectronics for localized drug delivery. *Small Methods*, 2024; 8(1). doi:10.1002/smtd.202301068.
19. He GQ, Li H, Liu J, Hu YL, Liu Y, Wang ZL, et al. Recent progress in implantable drug delivery systems. *Adv Mater*, 2024; 36(23). doi:10.1002/adma.202312530.
20. di Biase L, Tinkhauser G, Moraud EMM, Caminiti ML, Pecoraro PM, Di Lazzaro V. Adaptive, personalized closed-loop therapy for Parkinson's disease: biochemical, neurophysiological, and wearable sensing systems. *Expert Rev Neurother*, 2021; 21(12): 1371-1388. doi:10.1080/14737175.2021.2000392.
21. Marceglia S, Guidetti M, Harmsen IE, Loh A, Meoni S, Foffani G, et al. Deep brain stimulation: is it time to change gears by closing the loop? *J Neural Eng*, 2021; 18(6). doi:10.1088/1741-2552/ac3267.
22. Sasaki F, Oyama G, Sekimoto S, Nuermaimaiti M, Iwamuro H, Shimo Y, et al. Closed-loop programming using external responses for deep brain stimulation in Parkinson's disease. *Parkinsonism Relat Disord*, 2021; 84: 47-51. doi: 10.1016/j.parkreldis.2021.01.023.
23. Pavlov VA, Chavan SS, Tracey KJ. Bioelectronic medicine: from preclinical studies on the inflammatory reflex to new approaches in disease diagnosis and treatment. *Cold Spring Harb Perspect Med*, 2020; 10(3). doi:10.1101/cshperspect. a034140.
24. Olofsson PS, Bouton C. Bioelectronic medicine: an unexpected path to new therapies. *J Intern Med*, 2019; 286(3): 237-239. doi:10.1111/joim.12967.
25. Mickle AD, Won SM, Noh KN, Yoon J, Meacham KW, Xue Y, et al. A wireless closed-loop system for optogenetic peripheral neuromodulation. *Nature*, 2019; 565(7739): 361-365. doi:10.1038/s41586-018-0823-6.
26. Zhang G, Chen Y, Zhou W, Chen C, Liu Y. Bioenergy-based closed-loop medical systems for the integration of treatment, monitoring, and feedback. *Small Sci*, 2023; 3(10): 2300043. doi:10.1002/smssc.202300043.
27. Sun W, Lee J, Zhang S, Benyshek C, Dokmeci MR, Khademhosseini A. Engineering precision medicine. *Adv Sci (Weinh)*, 2019; 6(1): 1801039. doi:10.1002/advs.201801039.

28. Ahmed U, Chang YC, Zafeiropoulos S, Nassrallah Z, Miller L, Zanos S. Strategies for precision vagus neuromodulation. *Bioelectron Med*, 2022; 8(1): 9. doi:10.1186/s42234-022-00091-1.
29. Jiang L, Wu J. Emerging ultrasonic bioelectronics for personalized healthcare. *Prog Mater Sci*, 2023; 136: 101110. doi: 10.1016/j.pmatsci.2023.101110.
30. Fritz JR, Huston JM. Advances in bioelectronic medicine: noninvasive electrical, ultrasound and magnetic nerve stimulation. *Bioelectron Med*, 2020; 2(4): 143-150. doi:10.2217/bem-2020-0001.
31. Ye H, Fussenegger M. Optogenetic medicine: synthetic therapeutic solutions precision-guided by light. *Cold Spring Harb Perspect Med*, 2019; 9(9). doi:10.1101/cshperspect. a034371.
32. Berggren M, Głowacki ED, Simon DT, Stavrinidou E, Tybrandt K. In vivo organic bioelectronics for neuromodulation. *Chem Rev*, 2022; 122(5): 4826-4846.
33. Luan S, Williams I, Nikolic K, Constandinou TG. Neuromodulation: present and emerging methods. *Front Neuroeng*, 2014; 7: 27. doi:10.3389/fneng.2014.00027.
34. Schwab JM, Hamani C. The history and future of deep brain stimulation. *Neurotherapeutics*, 2008; 5(1): 3-13. doi: 10.1016/j.nurt.2007.11.002.
35. Zanos TP, Silverman HA, Levy T, Tsaava T, Battinelli E, Lorraine PW, et al. Identification of cytokine-specific sensory neural signals by decoding murine vagus nerve activity. *Proc Natl Acad Sci U S A.*, 2018; 115(21). doi:10.1073/pnas.1715198115.
36. Caravaca AS, Tsaava T, Goldman L, Silverman HA, Rojas MJ, Batty N, et al. A novel flexible cuff-like microelectrode for dual purpose, acute and chronic electrical interfacing with the mouse cervical vagus nerve. *J Neural Eng*, 2017; 14(6): 066005. doi:10.1088/1741-2552/aa89c9.
37. Pinho-Ribeiro FA, Baddal B, Haarsma R, O'Seaghdha M, Yang NJ, White JP, et al. Blocking neuronal signaling to immune cells treats streptococcal invasive infection. *Cell*, 2018; 173(5): 1083-1097.e22. doi: 10.1016/j.cell.2018.04.004.
38. Ravaine V, Ancla C, Catargi B. Chemically controlled closed-loop insulin delivery. *J Control Release*, 2008; 132(1): 2-11. doi: 10.1016/j.jconrel.2008.08.009.
39. Bakh NA, Cortinas AB, Weiss MA, Langer RS, Anderson DG, Gu Z, et al. Glucose-responsive insulin by molecular and physical design. *Nat Chem*, 2017; 9(10): 937-943. doi:10.1038/nchem.2857.
40. Wu Q, Wang L, Yu H, Wang J, Chen Z. Organization of glucose-responsive systems and their properties. *Chem Rev*, 2011; 111(12): 7855-7875. doi:10.1021/cr200027j.
41. Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. *Proc Natl Acad Sci U S A.*, 2015; 112(27): 8260-8265. doi:10.1073/pnas.1505405112.
42. Yu J, Zhang Y, Bomba H, Gu Z. Stimuli-responsive delivery of therapeutics for diabetes treatment. *Bioeng Transl Med*, 2016; 1(3): 323-337. doi:10.1002/btm2.10036.
43. Chen G, Yu J, Gu Z. Glucose-responsive microneedle patches for diabetes treatment. *J Diabetes Sci Technol*, 2019; 13(1): 41-48. doi:10.1177/1932296818778607.
44. Mo R, Jiang T, Di J, Tai W, Gu Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. *Chem Soc Rev*, 2014; 43(10): 3595-3629. doi:10.1039/C3CS60436E.
45. Bawa P, Pillay V, Choonara YE, du Toit LC. Stimuli-responsive polymers and their applications in drug delivery. *Biomed Mater*, 2009; 4(2): 022001. doi:10.1088/1748-6041/4/2/022001.

46. Bankar SB, Bule MV, Singhal RS, Ananthanarayan L. Glucose oxidase—an overview. *Biotechnol Adv*, 2009; 27(4): 489-501. doi: 10.1016/j.biotechadv.2009.04.003.
47. Bhat R, Ribes À, Mas N, Aznar E, Sancenón F, Marcos MD, et al. Thrombin-responsive gated silica mesoporous nanoparticles as coagulation regulators. *Langmuir*, 2016; 32(5): 1195-1200. doi: 10.1021/acs.langmuir.5b04175.
48. Stuart MAC, Huck WTS, Genzer J, Müller M, Ober C, Stamm M, et al. Emerging applications of stimuli-responsive polymer materials. *Nat Mater*, 2010; 9(2): 101-113. doi:10.1038/nmat2614.
49. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. *Nat Mater*, 2013; 12(11): 991-1003. doi:10.1038/nmat3776.
50. Owens DR. New horizons—alternative routes for insulin therapy. *Nat Rev Drug Discov*, 2002; 1(7): 529-540. doi:10.1038/nrd838.
51. Leelarathna L, Choudhary P, Wilmot EG, Lumb A, Street T, Kar P, et al. Hybrid closed-loop therapy: where are we in 2021? *Diabetes Obes Metab*, 2021; 23(3): 655-660. doi:10.1111/dom.14273.
52. Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. *Endocr Rev*, 2023; 44(2): 254-280. doi:10.1210/endrev/bnac022.
53. Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, et al. Automated insulin delivery: benefits, challenges, and recommendations. *Diabetologia*, 2023; 66(1): 3-22. doi:10.1007/s00125-022-05744-z.
54. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. *N Engl J Med*, 2010; 363(4): 311-320. doi:10.1056/NEJMoa1002853.
55. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. *N Engl J Med*, 2013; 369(22): 224-232. doi:10.1056/NEJMoa1303576.
56. Venkatesh KP, Brito G, Kamel Boulos MN. Health digital twins in life science and health care innovation. *Annu Rev Pharmacol Toxicol*, 2024; 64: 159-170. doi:10.1146/annurev-pharmtox-022123-022046.